Aug 2026· European Journal of Heart Failure· 0 citations
Medicine
TL;DR
The observed HF-cancer association is influenced by statistical methodology, shared risk factors, differences in surveillance intensity and cancer type, that confound analyses investigating possible causal biological links.
Abstract
Background
Cancer and heart failure (HF) frequently coexist due to population ageing and improved survival for both conditions. HF is a well-recognised complication of oncologic therapies and a potential association between HF and subsequent cancer incidence has been recently noticed. We therefore conducted a meta-analysis to quantify cancer incidence and mortality in patients with and without HF.
Methods
Databases were searched from inception to 15 February 2026. Data from observational studies and randomised trials on individuals with and without HF and reporting cancer incidence and/or mortality during follow-up were included. The main outcome of interest was the incidence of any cancer; secondary outcomes included site-specific cancer incidence (lung, colorectal, breast, and prostate) and all-cause, cardiovascular, and cancer-related mortality.
Results
Twelve studies comprising 8,979,195 individuals were included. HF was associated with a higher incidence of cancer (hazard ratio [HR] 1.33, 95% confidence interval [CI] 1.14-1.54), with substantial heterogeneity (I2 = 99.7%). Cancer site-specific analyses showed increased incidences of lung (HR 1.70, 95% CI 1.26-2.29), colorectal (HR 1.28, 95% CI 1.11-1.48), and breast (HR 1.19, 95% CI 1.04-1.37), but not prostate, cancer. Effect estimates varied according to analytical strategy: matched HF and non-HF cohorts reported higher risk estimates than those using covariate adjustment without matching. Mortality data were sparse and heterogeneous.
Conclusions
HF is associated with a higher incidence of cancer, although with marked heterogeneity among studies and cancer types. Mortality and cause of death were rarely reported. The observed HF-cancer association is influenced by statistical methodology, shared risk factors, differences in surveillance intensity and cancer type, that confound analyses investigating possible causal biological links. More granular and harmonised studies are required.
A substantial cardiovascular burden among cancer patients is confirmed while highlighting important limitations in the evidence base, and strengthening integrated cardio-oncology care and prioritising high-quality research are essential to improve risk stratification and patient outcomes.
S. A. Belachew, S. A. Mohammed, G. Garvey· Clinical and Experimental Me...· 0 citations
The manifold of CVD and CV health indicators increase the risk of new-onset cancer and cancer-related mortality, and the need for awareness of future cancer in patients with CVD is emphasized.
L. Yousif, P. Ameri, M. Vinci et al.· European Heart Journal, Supp...· 0 citations
Cancer remains a leading cause of mortality globally, while hypertension is the primary contributor to cardiovascular disease and premature death. These conditions frequently coexist; hypertension may precede cancer due to shared risk factors or arise during or after cancer treatment, partly as a result of the hypert...
Bahaa Mali, Ali Mali, Alaa Mali et al.· Scientific Reports· 0 citations
There is a substantial HF-related mortality burden across cancer patients, which is on the rise in recent years, and certain high-risk populations may be identified and cardio-oncology surveillance and targeted cardiovascular risk reduction strategies may be implemented among cancer survivors.
Abes A. Bautista Neughebauer, D. Talreja, A. Gaitanidis· Frontiers in Oncology· 0 citations
Evaluating the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and identifying factors associated with increased risk of cardiovascular disease highlights the need for sustained cardiovascular surveillance in breast cancer survivors.
V. Dvorovy, L. Kováčová, M. Selvek et al.· European Heart Journal, Supp...· 0 citations
It is recommended that patients with lung cancer undergo screening to assess their cardiovascular risk and related complications and it is recommended that patients with lung cancer undergo screening to assess their cardiovascular risk and related complications.
M. Mamedov, P. Skopin, A. K. Karimov· Russian Journal of Preventiv...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.